Results 121 to 130 of about 783,276 (359)
Airway spider or airway spiders? [PDF]
Flavia Petrini, Massimiliano Sorbello
openaire +3 more sources
Survivorship of Individuals With Double Heterozygosity for Achondroplasia and Type 2 Collagenopathy
ABSTRACT Historically, double heterozygosity, or a diagnosis of two separate, dominant genetic conditions, was often thought to be lethal in individuals with autosomal dominant skeletal dysplasias. In previously published studies of individuals with dual dysplasia diagnoses of achondroplasia and type 2 collagenopathy, infants died of respiratory ...
Valerie R. Schwartz+3 more
wiley +1 more source
Cystic fibrosis of the pancreas: structural changes in peripheral airways [PDF]
John R. Esterly, Ella H. Oppenheimer
openalex +1 more source
ABSTRACT Wisconsin syndrome is a very rare genetic condition characterized by coarse facies, prominent nasal tip, bushy high arched/upsweeping eyebrows, and a full/everted lower lip. Deletion of chromosome 3q24q25 region is considered critical for its manifestation.
Pankaj Prasun+2 more
wiley +1 more source
Effect of aerosol propellants and surfactants on airway resistance [PDF]
G. M. Sterling, John Batten
openalex +1 more source
ABSTRACT Natural History Studies can help inform clinician and caregiver expectations, form the basis of management guidelines, and provide a comparator for therapeutic intervention. In rare conditions, where collection of prospective longitudinal data is untimely and impractical, quasi‐natural history data—from multiple individuals of different ages ...
E. Woods+16 more
wiley +1 more source
Airway Resistance and Lung Volume in the Newborn Infant [PDF]
Carl F. Doershuk, LeRoy W. Matthews
openalex +1 more source
The Length of the Airway to the Bifurcation of the Trachea [PDF]
Richard R. Schellinger
openalex +1 more source
Elexacaftor–Tezacaftor–Ivacaftor Improves Sinonasal Outcomes in Young Children With Cystic Fibrosis
ABSTRACT Background Severe chronic rhinosinusitis (CRS) is a near universal manifestation of cystic fibrosis. Elexacaftor/tezacaftor/ivacaftor (ETI) is an oral, small molecule, highly effective Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) corrector–potentiator drug.
Amanda L. Stapleton+10 more
wiley +1 more source